Avalo Therapeutics
AVTX
4 hedge funds and large institutions have $2.94M invested in Avalo Therapeutics in 2016 Q3 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 0 reducing their positions, and 3 closing their positions.
86% more capital invested
Capital invested by funds: $1.58M → $2.94M (+$1.36M)
20% less funds holding
Funds holding: 5 → 4 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TWA
TCI Wealth Advisors
Tucson,
Arizona
|
+$10.5K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$10.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$29K |
| 2 |
RC
RBF Capital
San Francisco,
California
|
-$24K |
| 3 |
BCCM
Blue Clay Capital Management
Minneapolis,
Minnesota
|
-$11K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NMC
1
NEA Management Company
Timonium,
Maryland
| $2.52M | – | – | – |
|
|
PWAM
2
Park West Asset Management
San Francisco,
California
| $385K | – | – | – |
|
|
3
UBS Group
Zurich,
Switzerland
| $14K | +$10.5K | +1 | New |
|
|
TWA
4
TCI Wealth Advisors
Tucson,
Arizona
| $13K | +$10.5K | +1 | New |
|
|
BFA
5
BlackRock Fund Advisors
San Francisco,
California
| $6K | – | – | – |
|
|
AIM
6
Acrospire Investment Management
Chicago,
Illinois
| $3K | – | – | – |
|
7
Bank of America
Charlotte,
North Carolina
| $2K | – | – | – |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $2K | – | – | – |
|
|
9
Millennium Management
New York
| – | -$29K | -5 | Closed |
|
|
RC
10
RBF Capital
San Francisco,
California
| – | -$24K | -4 | Closed |
|
|
BCCM
11
Blue Clay Capital Management
Minneapolis,
Minnesota
| – | -$11K | -2 | Closed |
|
AVTX Hedge Fund Activity: Q3 2016 in Review
4 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q3 2016, worth a combined $2.94M — up 86% from $1.58M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of AVTX and 2 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest buyer was TCI Wealth Advisors, opening a new position worth an estimated $10.5K. The largest seller was Millennium Management, exiting entirely with an estimated $29K sold.
- 4 institutional investors held Avalo Therapeutics (AVTX) as of Q3 2016, down from 5 in Q2 2016.
- Funds reported $2.94M of Avalo Therapeutics stock for Q3 2016, up 86% quarter-over-quarter.
- 2 funds opened new Avalo Therapeutics positions in Q3 2016 and 3 closed out, a net change of -1 holder.
- The largest Avalo Therapeutics buyer in Q3 2016 was TCI Wealth Advisors, an estimated $10.5K added.
- The largest Avalo Therapeutics seller in Q3 2016 was Millennium Management, an estimated $29K sold.
Based on aggregated 13F filings for Q3 2016.